Ophthalmic Manifestations of Multisystem Inflammatory Syndrome in Children

Abstract

Objective The aims of this study were to determine the prevalence and clinical features of ophthalmic involvement in multisystem inflammatory syndrome in children (MIS-C) and to evaluate its association with other organ system involvement and the severity of the disease.

Methods The demographic data and information on the ophthalmologic and other systemic organ manifestations, laboratory findings, treatment modalities, and clinical outcomes of 97 patients with MIS-C were retrospectively obtained from their hospital records. Sixty-two patients with MIS-C who were examined by ophthalmologists were included in the study. Statistical analysis was performed using R version 3.6.0, and a p-value < 0.05 was accepted as statistically significant.

Results The patients' median age was 82 months (range, 11–204 months). Of the patients, 62.9% were male. The most common systemic involvements were mucocutaneous (83.9%) and cardiovascular (82.3%). Kawasaki disease was clinically observed in 71% of the patients (incomplete form, 53.2%). Ophthalmic involvement was observed in 39 patients (62.9%). Thirty-two patients (51.6%) had conjunctival hyperemia; 29 (48.4%) lid edema; 7 follicular conjunctivitis; 3 uveitis; 2 subconjunctival hemorrhage; and 1 episcleritis. The patients with ophthalmic involvement were 6.4 times (95% confidence interval [CI], 1.49–27.48; p = 0.013) more likely to exhibit cardiac involvement and 3.53 times (95% CI, 1.35–9.63; p = 0.012) more likely to have severe disease.

Conclusion Conjunctival hyperemia, lid edema, and follicular conjunctivitis were observed in at least half of the patients with MIS-C, and those with ophthalmic involvement had a higher risk of cardiac involvement or severe disease.

Keywords

COVID-19 - multisystem - inflammatory syndrome in children - ophthalmic manifestation - cardiac involvement

Availability of Data and Material

The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.

Code Availability

All source codes are available within the article [and/or] its supplementary materials.

Authors' Contributions

M.E. was responsible for substantial contributions to conception and design, acquisition of data, analysis, and interpretation of data; and drafting the article and revising it critically for important intellectual content.

B.B. was responsible for substantial contributions to conception and design, acquisition of data, analysis and interpretation of data; and drafting the article;

S.A.D. was responsible for substantial contributions to conception and design, acquisition of data, analysis and interpretation of data; and revising it critically for important intellectual content;

G.A. was responsible for substantial contributions to conception and design, acquisition of data, analysis and interpretation of data; and revising it critically for important intellectual content.

S.K.T.O. was responsible for substantial contributions to conception and design, acquisition of data, analysis and interpretation of data; and revising it critically for important intellectual content.

A.S. was responsible for substantial contributions to conception and design, acquisition of data, analysis and interpretation of data; and revising it critically for important intellectual content.

M.K.K. was responsible for substantial contributions to conception and design, acquisition of data, analysis and interpretation of data; and revising it critically for important intellectual content.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

Ethical Approval

The study protocols were approved by the Selcuk University Faculty of Medicine ethics committee

Consent to Participate

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

Consent for Publication

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. The manuscript is not under publication or consideration for publication elsewhere.

Publication History

Received: 08 November 2022

Accepted: 31 March 2023

Article published online:
01 May 2023

• References

• 1 Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395 (10237): 1607-1608
• 2 Dufort EM, Koumans EH, Chow EJ. et al; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem inflammatory syndrome in children in New York State. N Engl J Med 2020; 383 (04) 347-358
• 3 Reiff DD, Cron RQ. Who would have predicted multisystem inflammatory syndrome in children?. Curr Rheumatol Rep 2022; 24 (01) 1-11
• 4 Henderson LA, Canna SW, Friedman KG. et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis Rheumatol 2022; 74 (04) e1-e20
• 5 Godfred-Cato S, Abrams JY, Balachandran N. et al. Distinguishing multisystem inflammatory syndrome in children from COVID-19, Kawasaki disease and toxic shock syndrome. Pediatr Infect Dis J 2022; 41 (04) 315-323
• 6 Baradaran A, Malek A, Moazzen N, Abbasi Shaye Z. COVID-19 associated multisystem inflammatory syndrome: a systematic review and meta-analysis. Iran J Allergy Asthma Immunol 2020; 19 (06) 570-588
• 7 Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr 2021; 180 (07) 2019-2034
• 8 Belay ED, Abrams J, Oster ME. et al. Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic. JAMA Pediatr 2021; 175 (08) 837-845
• 9 Lo T-C, Chen Y-Y. Ocular and systemic manifestations in paediatric multisystem inflammatory syndrome associated with COVID-19. J Clin Med 2021; 10 (13) 2953
• 10 Yilmaz Ciftdogan D, Ekemen Keles Y, Cetin BS. et al. COVID-19 associated multisystemic inflammatory syndrome in 614 children with and without overlap with Kawasaki disease-Turk MIS-C study group. Eur J Pediatr 2022; 181 (05) 2031-2043
• 11 Centers for Disease Control and Prevention. Information for healthcare providers about M ultisystem Infammatory Syndrome in Children (MIS-C). Accessed October 2, 2022, at: http s:// www.cdc.gov/mis/mis-c/hcp
• 12 Jonat B, Gorelik M, Boneparth A. et al. Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 in a Children's Hospital in New York City: patient characteristics and an institutional protocol for evaluation, management, and follow-up. Pediatr Crit Care Med 2021; 22 (03) e178-e191
• 13 Feldstein LR, Rose EB, Horwitz SM. et al; Overcoming COVID-19 Investigators, CDC COVID-19 Response Team. etal; Overcoming COVID-19 investigators; CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020; 383 (04) 334-346
• 14 Young TK, Shaw KS, Shah JK. et al. Mucocutaneous manifestations of multisystem inflammatory syndrome in children during the COVID-19 pandemic. JAMA Dermatol 2021; 157 (02) 207-212
• 15 Aggarwal K, Agarwal A, Jaiswal N. et al. Ocular surface manifestations of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. PLoS One 2020; 15 (11) e0241661
• 16 Al-Namaeh M. COVID-19 and conjunctivitis: a meta-analysis. Ther Adv Ophthalmol 2021; 13: 25 158414211003368
• 17 Chen YY, Yen YF, Huang LY, Chou P. Manifestations and virus detection in the ocular surface of adult COVID-19 patients: a meta-analysis. J Ophthalmol 2021; 2021: 9997631
• 18 Binotti W, Hamrah P. COVID-19-related Conjunctivitis Review: Clinical features and management. Ocul Immunol Inflamm 2022; (e-pub ahead of print).
• 19 Güemes-Villahoz N, Burgos-Blasco B, García-Feijoó J. et al. Conjunctivitis in COVID-19 patients: frequency and clinical presentation. Graefes Arch Clin Exp Ophthalmol 2020; 258 (11) 2501-2507
• 20 Angurana SK, Kumar A, Malav T. Hemorrhagic nonpurulent conjunctivitis in MIS-C. Indian J Pediatr 2022; 89 (02) 195-196
• 21 Matsubara D, Tamura D, Kasuya Y. et al. Case report: anterior scleritis presenting as a primary ocular manifestation in multisystem inflammatory syndrome in children with COVID-19. Front Pediatr 2022; 10: 943652
• 22 Bettach E, Zadok D, Weill Y, Brosh K, Hanhart J. Bilateral anterior uveitis as a part of a multisystem inflammatory syndrome secondary to COVID-19 infection. J Med Virol 2021; 93 (01) 139-140
• 23 Öztürk C, Yüce Sezen A, Savaş Şen Z, Özdem S. Bilateral acute anterior uveitis and corneal punctate epitheliopathy in children diagnosed with multisystem inflammatory syndrome secondary to COVID-19. Ocul Immunol Inflamm 2021; 29 (04) 700-704
• 24 Arkan İ, Demir ST, Livan EH, Elçioğlu MN. Ocular manifestations of multisystem inflammatory syndrome in children with COVID-19. Pediatr Infect Dis J 2021; 40 (09) e356-e358
• 25 Marinho PM, Marcos AAA, Romano AC, Nascimento H, Belfort Jr R. Retinal findings in patients with COVID-19. Lancet 2020; 395 (10237): 1610
• 26 Marinho PM, Marcos AAA, Branco AMC. et al. COVID-19 retinal findings in patients admitted to intensive care units and wards. Ocul Immunol Inflamm 2021; 29 (04) 705-708
• 27 Zago Filho LA, Lima LH, Melo GB, Zett C, Farah ME. Vitritis and outer retinal abnormalities in a patient with COVID-19. Ocul Immunol Inflamm 2020; 28 (08) 1298-1300
• 28 Verkuil LD, Liu GT, Brahma VL, Avery RA. Pseudotumor cerebri syndrome associated with MIS-C: a case report. Lancet 2020; 396 (10250): 532
• 29 Bilen NM, Sahbudak Bal Z, Yildirim Arslan S, Kanmaz S, Kurugol Z, Ozkinay F. Multisystem inflammatory syndrome in children presenting with pseudotumor cerebri and a review of the literature. Pediatr Infect Dis J 2021; 40 (12) e497-e500
• 30 Dhaliwal M, Tyagi R, Malhotra P. et al. Mechanisms of immune dysregulation in COVID-19 are different from SARS and MERS: a perspective in context of Kawasaki Disease and MIS-C. Front Pediatr 2022; 10: 790273
• 31 Tiwari V, Daniel AA. Multisystem inflammatory syndrome in children: a year in review. Eur J Rheumatol 2022; 9 (03) 167-175
• 32 Wu EY, Campbell MJ. Cardiac manifestations of multisystem inflammatory syndrome in children (MIS-C) following COVID-19. Curr Cardiol Rep 2021; 23 (11) 168
• 33 Kang JM, Jung J, Kim YE. et al. Temporal correlation between Kawasaki Disease and infectious diseases in South Korea. JAMA Netw Open 2022; 5 (02) e2147363
• 34 Ohno S, Miyajima T, Higuchi M. et al. Ocular manifestations of Kawasaki's disease (mucocutaneous lymph node syndrome). Am J Ophthalmol 1982; 93 (06) 713-717
• 35 Abrams JY, Oster ME, Godfred-Cato SE. et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health 2021; 5 (05) 323-331
• 36 Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services, CDC. Accessed October 02, 2022 at: https://covid.cdc.gov/covid-data-tracker
• 37 Ahmed M, Advani S, Moreira A. et al. Multisystem inflammatory syndrome in children: a systematic review. EClinicalMedicine 2020; 26: 100527
• 38 Bowen A, Miller AD, Zambrano LD. et al. Demographic and clinical factors associated with death among persons <21 years old with multisystem inflammatory syndrome in children-United States, February 2020-March 2021. Open Forum Infect Dis 2021; 8 (08) ofab388